
Stocks Market
Sothema's Acquisition of Ramo Pharm Moves Forward with Competition Council Review
Moroccan pharmaceutical giant Sothema has taken a significant regulatory step toward acquiring 100% of dietary supplement distributor Ramo Pharm. The Competition Council officially registered the transaction notification on November 5, 2026, launching a public consultation period that runs until November 19. This strategic move aims to strengthen Sothema's position in the consumer health sector as part of its broader diversification strategy beyond traditional pharmaceuticals.
Listen to this article
Unlock audio versions of premium articles and more with a Pro subscription.
The proposed takeover of Casablanca-based Ramo Pharm by listed pharmaceutical company Sothema has entered a critical regulatory phase. On Thursday, November 5, 2026, Morocco's Competition Council published formal notification of the transaction, marking eight days since the parties announced their agreement on October 28.
Transaction Details and Regulatory Process
The Competition Council confirmed receipt of the economic concentration filing involving Sothema's planned acquisition of full ownership and voting rights in Ramo Pharm. The regulatory body has opened a window for interested third parties to submit observations regarding the deal, with submissions accepted until November 19, 2026.
According to the Council's statement, the transaction concerns the dietary supplement distribution market. Ramo Pharm specializes in designing and marketing nutritional supplements in Morocco's growing wellness sector.
Strategic Rationale Behind the Deal
For Sothema, this acquisition represents a calculated expansion into the consumer health segment through its Wellness & Consumer Health division. The move aligns with the pharmaceutical group's ongoing diversification efforts, following its earlier purchase of Soludia Maghreb, which strengthened its foothold in the dialysis market.
The dietary supplement sector offers Sothema access to the expanding over-the-counter health products market, complementing its prescription pharmaceutical business and medical equipment operations.
Regulatory Approval Still Pending
It's important to note that the public notification does not constitute approval of the transaction. The Competition Council emphasized that publication of the filing does not indicate whether the submitted documentation is complete. Final completion of the acquisition remains contingent upon obtaining regulatory clearance, in line with the suspensive conditions outlined by Sothema when the deal was announced on October 28.
The coming weeks will determine whether any market participants raise concerns about competitive effects of combining Sothema's distribution capabilities with Ramo Pharm's dietary supplement portfolio.